A$30 million Equity Placement Agreement with L1 Capital
Filed with ASX · · 5 pages · English
• Initial Placement of A$500,000 in ordinary shares at A$0.10 each (being the closing bid price yesterday, 8 June 2022) and 15,000,000 unlisted options exercisable at A$0.255 each expiring 31 March 2024 to be issued within seven days • Equity placement facility of up to a total of A$30 million over 24 months with L1 Capital, a leading global investment manager, by way of separate placements (the s
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Strategic manufacturing partnership with WuXi ATU
- Security Class Reinstatement to Quotation CHMO
- CDH17 CAR t preclinical data featured in Nature Cancer
- Completion of retail component of Entitlement Offer
- Security Class Suspension from Quotation CHMO
Later from Chimeric Therapeutics
- Licenses viral vector technology from Penn for CDH17
- Patent received in Japan for CLTX CAR technology
- Exclusive license agreement with CWRU for CORE-NK platform
- Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trial
- Follow up period completed for 3rd cohort in CHM 1101 trial
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics